Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial infrastructure, instead of partnering outside the U.S. as it had originally intended. “We’ve concluded that the best way for us to achieve our goals with our rich pipeline is to direct our own global development and commercial strategies and to operationalize these both inside and outside the U.S. through our own organization,” Mark Goldsmith, president and CEO of Revolution Medicines (Revmed), told investors June 24. Read More
Atopic dermatitis data from Nektar Therapeutics Inc. put investors even more in the mood for further results with rezpegaldesleukin (rezpeg), an IL-2 pathway agonist and regulatory T-cell proliferator, also in the works for severe to very severe alopecia areata. Read More
Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage” of the revenue generated by Spikevax (elasomeran), its mRNA-based vaccine for COVID-19. Read More
“I expressed deep concerns with your nomination, Secretary Kennedy, and somehow, unfortunately, you have exceeded my expectations in the worst possible ways,” U.S. Rep. Frank Pallone, D-N.J., told Health and Human Services (HHS) Secretary Robert Kennedy during a June 24 House subcommittee hearing. Read More
At the 11th Congress European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new data on using CAR T cells in autoimmune neurological conditions. Read More
The Department of Health and Human Services and private payers have promised to streamline the controversial prior authorization processes in a bid to reduce the attendant controversies. Read More
Barely a day before the eight new members of the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) are supposed to hold their first meeting, Sen. Bill Cassidy, R-La., called for the June 25 meeting to be postponed. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Cidara, Compass, Eli Lilly, Exelixis, Forte, H. Lundbeck, Immutep, J&J, Leap, Merck, Novo Nordisk, Pleopharma, Roche, Vertex. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Chuang, Carisma, Denovo, Enzon, Formation Bio, Hyloris, Idorsia, Kuvatris, Leap, Ono, Orthocellix, Purdue, Sanofi, Simcere, Viskase, Vertex. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alvotech, Advanz, Argenx, GSK, Idorsia, Incyte, Novadip, Partner, PTC, Revolution, Sanofi, Simcere. Read More
